Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. (Nasdaq: IMRA) announced that it will present data from the Phase 2a open-label extension study of tovinontrine (IMR-687) for sickle cell disease at the ASH Annual Meeting on December 11-14, 2021. The presentation will include 12-month vaso-occlusive crisis (VOC) data. Additionally, the company will introduce IMR-261, a novel oral Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in sickle cell models. Both assets are crucial in their efforts to develop therapeutics for hemoglobin-related disorders.
Imara Inc. (Nasdaq: IMRA) is set to participate in two virtual investor conferences in September 2021. The company will take part in the SVB Leerink CybeRx Series on September 22 and 23, focusing on neuromuscular and rare diseases. Additionally, Rahul Ballal, Ph.D., President and CEO, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 2:00 p.m. ET. A live webcast of the presentation will be available on the company’s website.
Imara is advancing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia.
Imara Inc. (Nasdaq: IMRA) announced participation in three key virtual investor conferences in September 2021. The events include the Citi 16th Annual BioPharma Virtual Conference on September 10, where Dr. Rahul Ballal will discuss benign hematology, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring a pre-recorded presentation from Dr. Ballal. Additionally, on September 15, both Dr. Ballal and Dr. Ken Attie will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference.
Imara Inc. (Nasdaq: IMRA) reported positive progress in its clinical trials for IMR-687 (tovinontrine) in sickle cell disease and beta-thalassemia, with accelerated patient enrollment and expected interim data in Q4 2021. The company completed a $50 million public offering, extending its cash runway into 2022. Q2 2021 net loss increased to $13.2 million, or $0.74 per share, from $10.2 million, or $0.59 per share, in Q2 2020. R&D expenses rose due to clinical developments. Financial guidance estimates R&D expenses between $42.5 million and $47.5 million for 2021.
Imara Inc. announced the completion of patient enrollment in its Ardent Phase 2b clinical trial of IMR-687 for sickle cell disease. The trial aims to evaluate the safety and efficacy of this potent PDE9 inhibitor. Interim analysis results are expected in Q4 2021, with primary endpoint readout anticipated in Q1 2022. The USAN Council has adopted tovinontrine as the generic name for IMR-687, highlighting its potential global impact.
Imara Inc. (Nasdaq: IMRA) will host a conference call on August 6, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and recent business updates. The call can be accessed domestically at 1 (833) 519-1307 or internationally at +1 (914) 800-3873 with conference ID 6499377. Imara is focused on developing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia. The drug is a selective inhibitor of PDE9 and aims to provide a multimodal mechanism of action, improving patient outcomes.
Imara Inc. (Nasdaq: IMRA) announced its public offering of shares at $6.00 each, raising gross proceeds of $50 million before expenses. The offering, expected to close on July 16, 2021, will allow the company to further develop its therapeutics for rare genetic disorders. Underwriters have a 30-day option to purchase an additional $7.5 million in shares. The shares are being offered under a previously filed shelf registration statement with the SEC.
Imara Inc. (Nasdaq: IMRA) announced a proposed underwritten public offering of $50 million of common stock, all offered by the Company. The offering is subject to market conditions, with a potential additional $7.5 million option for underwriters. This move follows a shelf registration statement filed on April 1, 2021. Imara is focused on developing therapies for rare genetic hemoglobin disorders, including its lead drug candidate, IMR-687, for sickle cell disease and beta-thalassemia. The timing and terms of the offering remain uncertain.
Imara Inc. has elected Dr. Laura A. Williams to its Board of Directors, bringing over 25 years of drug development and patient advocacy experience. Dr. Williams, currently the Senior VP at Ardelyx, is noted for her leadership in clinical trials and commitment to patient needs. Her expertise is expected to greatly aid Imara in advancing its lead therapeutic, IMR-687, for treating sickle cell disease and beta-thalassemia. The announcement follows the departure of Mette Kirstine Agger from the Board after five years.
Imara has expanded its Real Impact community support initiative, awarding 30 grants totaling $150,000 to nonprofit organizations assisting patients with sickle cell disease and beta-thalassemia. This year’s funding increased by $25,000 from 2020. The grants, assessed by external reviewers, will impact 16 states and focus on social determinants of health, virtual programming, and capacity enhancement for organizations. The initiative aims to improve the lives of affected individuals and their families by supporting local community organizations.